IGHE and asthma: Notably, newborn mice with the lower dose of LPS (3d1μgLPS/OVA) were significantly protected from asthma with significantly reduced AHR (p < 0.05, Supplementary Figure 2A), significantly reduced peribronchial and perivascular inflammation in lung tissues (p < 0.05, Supplementary Figure 2B), significantly reduced serum OVA-specific IgE levels (p < 0.05, Supplementary Figure 2C), and significantly reduced bronchoalveolar lavage fluid (BALF) levels of pro-eosinophilic/neutrophilic cytokines (p < 0.05, Supplementary Figure 3C).